The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Acute Systemic Infusion of Bupropion Decrease Formalin Induced Pain Behavior in Rat

  • Naderi, Somayyeh (Danesh Pey Hadi Co., Faculty of Medicine, Urmia University of Medical Sciences) ;
  • Pakdel, Firouz Ghaderi (Neurophysiology Resaerch Center, Faculty of Medicine, Urmia University of Medical Sciences) ;
  • Osalou, Mostafa Ashrafi (Department of Histology & Embryology, School of Medicine, Dokuz EyluL University (DEU)) ;
  • Cankurt, Ulker (Department of Histology & Embryology, School of Medicine, Dokuz EyluL University (DEU))
  • Received : 2013.09.24
  • Accepted : 2014.03.03
  • Published : 2014.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The chronic pain can disturb physical, psychological, and social performances. Analgesic agents are widely used but some antidepressants (ADs) showed analgesia also. Bupropion is using for smoke cessation but it can change morphine withdrawal signs such as pain. This study tested the acute systemic effect of bupropion on formalin induced pain behavior in rats. Methods: Wistar male healthy rats were divided into 7 groups (control, sham, and 5 treated groups with 10, 30, 90, 120, and 200 mg/kg of bupropion, i.p.). The bupropion injected 3 hours prior to formalin induced pain behavior. Formalin (50 ${\mu}l$, 2.5%) was injected subcutaneously in dorsal region of right hindpaw in all animals. Nociceptive signs were observed continuously on-line and off-line each minute. Common pain scoring was used for pain assessment. Results: The analysis of data by one-way ANOVA showed that bupropion can reduce pain scores in the second phase but not in first phase. Bupropion decreased the licking/biting duration significantly in first and second phase of formalin test. Conclusions: The results showed that bupropion has analgesic effects at systemic application. The change of second phase of the pain behavior was significant and it revealed that central mechanisms involve in bupropion analgesia.

Keywords

References

  1. Kang SS, Jung JW, Song CK, Yoon YJ, Shin KM. A new anterior approach for fluoroscopy-guided suprascapular nerve block - a preliminary report -. Korean J Pain 2012; 25: 168-72. https://doi.org/10.3344/kjp.2012.25.3.168
  2. Park HJ, Moon DE. Pharmacologic management of chronic pain. Korean J Pain 2010; 23: 99-108. https://doi.org/10.3344/kjp.2010.23.2.99
  3. Le Bars D, Gozariu M, Cadden SW. Acute pain measurement in animals. Part 1. Ann Fr Anesth Reanim 2001; 20: 347-65. https://doi.org/10.1016/S0750-7658(01)00381-1
  4. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-74. https://doi.org/10.1016/0304-3959(77)90130-0
  5. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17. https://doi.org/10.1016/0304-3959(92)90003-T
  6. Vaccarino AL, Chorney DA. Descending modulation of central neural plasticity in the formalin pain test. Brain Res 1994; 666: 104-8. https://doi.org/10.1016/0006-8993(94)90288-7
  7. Lebrun P, Manil J, Colin F. Formalin-induced central sensitization in the rat: somatosensory evoked potential data. Neurosci Lett 2000; 283: 113-6. https://doi.org/10.1016/S0304-3940(00)00934-4
  8. Abbadie C, Taylor BK, Peterson MA, Basbaum AI. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain 1997; 69: 101-10. https://doi.org/10.1016/S0304-3959(96)03285-X
  9. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, et al. Bupropion: a review of its mechanism of anti- depressant activity. J Clin Psychiatry 1995; 56: 395-401.
  10. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother 2007; 8: 457-66. https://doi.org/10.1517/14656566.8.4.457
  11. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12: 178-207. https://doi.org/10.1111/j.1527-3458.2006.00178.x
  12. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57: 1583-8. https://doi.org/10.1212/WNL.57.9.1583
  13. El Mansari M, Ghanbari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008; 55: 1191-8. https://doi.org/10.1016/j.neuropharm.2008.07.028
  14. Katz J, Pennella-Vaughan J, Hetzel RD, Kanazi GE, Dworkin RH. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 2005; 6: 656-61. https://doi.org/10.1016/j.jpain.2005.05.002
  15. Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain 2000; 16: 6-11. https://doi.org/10.1097/00002508-200003000-00002
  16. Shah TH, Moradimehr A. Bupropion for the treatment of neuropathic pain. Am J Hosp Palliat Care 2010; 27: 333-6. https://doi.org/10.1177/1049909110361229
  17. Ghaderi Pakdel F, Naderi S, Zare S. The opposite effect of intra-VTA bupropion on chewing and escape attendance behaviors of morphine withdrawal syndrome in rat. Urmia Med J 2011; 21: 415-22.
  18. Mokhtari Hashtjin M, Zare S, Ghaderi Pakdel F, Heysieattalab S. The effect of intra-VTA injection of Bupropion on sub- missive defensive aggressive behavior induced by electrical foot shock of rat. Pharm Sci 2010; 16: 125-30.
  19. Jahanbani M, Nasri S, Ghaderi Pakdel F, Cankurt U, Shahabi P, Amirabadi S, et al. The effect of acute intra Locus Coeruleus (LC) microinfusion of bupropion on formalin induced pain behavior in rat. Basic Clin Neurosci 2014; 5: 31-41.
  20. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7: 106-13. https://doi.org/10.4088/PCC.v07n0305
  21. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977; 53: 309-14. https://doi.org/10.1007/BF00492370
  22. Sampson D, Willner P, Muscat R. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology (Berl) 1991; 104: 491-5. https://doi.org/10.1007/BF02245655
  23. Thaler KJ, Morgan LC, Van Noord M, Gaynes BN, Hansen RA, Lux LJ, et al. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 2012; 29: 495-505. https://doi.org/10.1002/da.21951
  24. Gallagher RM. Management of neuropathic pain: translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain 2006; 22: S2-8. https://doi.org/10.1097/01.ajp.0000193827.07453.d6
  25. Jackson KC 2nd, St Onge EL. Antidepressant pharmacotherapy: considerations for the pain clinician. Pain Pract 2003; 3: 135-43. https://doi.org/10.1046/j.1533-2500.2003.03020.x
  26. Sharp J, Keefe B. Psychiatry in chronic pain: a review and update. Curr Psychiatry Rep 2005; 7: 213-9. https://doi.org/10.1007/s11920-005-0056-x
  27. Hawley P. Nontricyclic antidepressants for neuropathic pain #187. J Palliat Med 2009; 12: 476-7. https://doi.org/10.1089/jpm.2009.9629
  28. Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont) 2008; 5: 16-9.
  29. Miller A, Rabe-Jablonska J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain--a review. Psychiatr Pol 2005; 39: 21-32.
  30. West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol 2009; 12: 627-41. https://doi.org/10.1017/S1461145708009474
  31. Grant MM, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 2001; 49: 117-29. https://doi.org/10.1016/S0006-3223(00)00936-7
  32. Martin WJ, Gupta NK, Loo CM, Rohde DS, Basbaum AI. Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing. Pain 1999; 80: 57-65. https://doi.org/10.1016/S0304-3959(98)00194-8
  33. Taylor BK, Roderick RE, Basbaum AI. Brainstem noradrenergic control of nociception is abnormal in the spontaneously hypertensive rat. Neurosci Lett 2000; 291: 139-42. https://doi.org/10.1016/S0304-3940(00)01389-6
  34. Tsuruoka M, Matsutani K, Maeda M, Inoue T. Coeruleotrigeminal inhibition of nociceptive processing in the rat trigeminal subnucleus caudalis. Brain Res 2003; 993: 146-53. https://doi.org/10.1016/j.brainres.2003.09.023
  35. Tsuruoka M, Arai YC, Nomura H, Matsutani K, Willis WD. Unilateral hindpaw inflammation induces bilateral activation of the locus coeruleus and the nucleus subcoeruleus in the rat. Brain Res Bull 2003; 61: 117-23. https://doi.org/10.1016/S0361-9230(03)00099-6
  36. Liu L, Tsuruoka M, Maeda M, Hayashi B, Inoue T. Coeruleospinal inhibition of visceral nociceptive processing in the rat spinal cord. Neurosci Lett 2007; 426: 139-44. https://doi.org/10.1016/j.neulet.2007.06.030
  37. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155: 52-7. https://doi.org/10.1007/s002130000665
  38. Aston-Jones G, Bloom FE. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1981; 1: 887-900.
  39. Cedarbaum JM, Aghajanian GK. Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sci 1978; 23: 1383-92. https://doi.org/10.1016/0024-3205(78)90398-3
  40. Hajos M, Engberg G, Elam M. Reduced responsiveness of locus coeruleus neurons to cutaneous thermal stimuli in capsaicin-treated rats. Neurosci Lett 1986; 70: 382-7. https://doi.org/10.1016/0304-3940(86)90584-7
  41. Chapman V, Suzuki R, Dickenson AH. Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6. J Physiol 1998; 507: 881-94. https://doi.org/10.1111/j.1469-7793.1998.881bs.x
  42. Pertovaara A, Kontinen VK, Kalso EA. Chronic spinal nerve ligation induces changes in response characteristics of nociceptive spinal dorsal horn neurons and in their descending regulation originating in the periaqueductal gray in the rat. Exp Neurol 1997; 147: 428-36. https://doi.org/10.1006/exnr.1997.6555
  43. Viisanen H, Pertovaara A. Influence of peripheral nerve injury on response properties of locus coeruleus neurons and coeruleospinal antinociception in the rat. Neuroscience 2007; 146: 1785-94. https://doi.org/10.1016/j.neuroscience.2007.03.016
  44. Alba-Delgado C, Borges G, Sanchez-Blazquez P, Ortega JE, Horrillo I, Mico JA, et al. The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl) 2012; 221: 53-65. https://doi.org/10.1007/s00213-011-2542-7
  45. Rosenberg MB, Carroll FI, Negus SS. Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain 2013; 14: 246-59. https://doi.org/10.1016/j.jpain.2012.11.006
  46. Mico JA, Berrocoso E, Ortega-Alvaro A, Gibert-Rahola J, Rojas-Corrales MO. The role of 5-HT1A receptors in research strategy for extensive pain treatment. Curr Top Med Chem 2006; 6: 1997-2003. https://doi.org/10.2174/156802606778522195
  47. Campbell LC, Clauw DJ, Keefe FJ. Persistent pain and depression: a biopsychosocial perspective. Biol Psychiatry 2003; 54: 399-409. https://doi.org/10.1016/S0006-3223(03)00545-6
  48. Amirabadi S, Ghaderi Pakdel F, Shahabi P, Naderi S. Microinfusion of bupropion inhibits putative GABAergic ventral tegmental area neuronal activity. Basic Clin Neurosci 2014 [in press].

Cited by

  1. Pharmacological modulation of neuropathic pain-related depression of behavior vol.27, pp.4, 2016, https://doi.org/10.1097/FBP.0000000000000207